Alembic Pharmaceuticals is currently trading at RS. 1000.60, up by 10.95 points or 1.11% from its previous close of RS. 989.65 on the BSE.

The stock opened at RS. 999.05 and hit an intraday high of RS. 1010.00 and a low of RS. 980.00. So far, 20,842 shares have been traded on the counter.

Classified under BSE group 'A', the stock with a face value of RS. 2 had touched a 52-week high of RS. 1296.15 on October 9, 2024, and a 52-week low of RS. 725.60 on March 3, 2025. In the past week, the scrip recorded a high of RS. 1107.80 and a low of RS. 963.75. The current market capitalization of the company stands at RS. 19539.36 crore.

Promoters hold 69.67% of the company's shares, while institutional and non-institutional investors hold 20.37% and 9.96% respectively.

In a significant move, Alembic Pharmaceuticals’ wholly-owned subsidiary, Alembic Pharmaceuticals Inc., is set to acquire US-based Utility Therapeutics (Utility). The acquisition aims to commercialize both an approved product and a pipeline product owned by Utility in the U.S. market. The transaction, valued at around $12 million, will be completed in a staggered manner within 30 days based on milestone achievements.

Alembic Pharmaceuticals, established in 1907, is a vertically integrated research and development-driven pharmaceutical company at the forefront of healthcare innovation.